Kresimir Kostović

Kresimir Kostović

Auto-generated profile, based on publicly available information

Kresimir Kostović

Department of Dermatovenerology, University Hospital Center Zagreb and School of Medicine, University of Zagreb, Zagreb, Croatia.

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2014 in Inflammation & Allergy - Drug Targets
Verified
Journal Article
Closed access
PDF file
SRSaida Rezakovic
Saida Rezakovic
ZPZrinjka Pastar
Zrinjka Pastar
KKKresimir Kostovic
Kresimir Kostovic
Multidrug antituberculosis regimen is associated with diverse clinical patterns of cutaneous adverse drug reactions (CADR), ranging from mild and moderate such as pruritus, maculopapular exanthems, lichenoid eruptions, fixed drug eruptions and urticaria to severe and even life threatening ones like acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). These adverse reactions to antituberculosis drugs are commonly observed adverse events. This is of particular importance for high HIV prevalence settings and developing countries where tuberculosis is common infection resulting in higher occurrence rate of these reactions. There is still significant heterogenity in definition and classification of CADR, as well as diversity in treatment modalities following adverse reactions and rechallenge management. The aim of this review is to discuss clinical presentation, occurrence of CADR caused by antituberculosis drugs, to identify risk factors for intolerance of the standard therapy as well as to draw attention to importance of multi-disciplinary approach, early detection, prompt diagnosis and in time management of antituberculosis drugs associated CADR. CADR can cause significant treatment interruption and alteration, resulting in increased risk of treatment failure, drug resistance, relapses and increased risk of complications including even lethal outcome. Finally, it can be concluded that it is of great importance to identify the best possible treatment and preventive regimens in order to enable continuity of the antituberculosis therapy to the full extent.

1 December 2012
Verified
Journal Article
Closed access
KKKresimir Kostović
Kresimir Kostović
ZPZrinjka Pastar
Zrinjka Pastar
RCRomana Ceović
Romana Ceović
ZMZrinka Bukvić Mokos
Zrinka Bukvić Mokos
DBDaska Stulhofer Buzina
Daska Stulhofer Buzina
ASAndrija Stanimirović
Andrija Stanimirović

20 June 2013 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
RCRomana Ceovic
Romana Ceovic
IJIvana Jovanovic
Ivana Jovanovic
KKKresimir Kostovic
Kresimir Kostovic
JRJaka Rados
Jaka Rados
SDSnjezana Dotlic
Snjezana Dotlic
DLDavorin Loncaric
Davorin Loncaric
Primary cutaneous follicle center lymphoma is an indolent primary cutaneous B-cell lymphoma originating from the follicle center cells, composed of a combination of centrocytes (small and large cleaved cells) and centroblasts (large noncleaved cells) with a follicular, follicular/diffuse, or diffuse growth pattern. Lesions are mostly located on the head, neck and trunk. A case is presented of a 56-year-old male patient with primary cutaneous follicle center lymphoma, with lesions involving the skin of the back, shoulders, presternal area and right forearm. As the patient presented a disseminated cutaneous form of the disease that involved several anatomical regions, complete work-up was followed by superficial fractionated radiotherapy of eight fields in VI expositions, with total irradiation dose of 1400 cGy upon the following fields: right and left pectoral region, left and right shoulders, right suprascapular region, and proximal third of the right forearm. Total irradiation dose applied upon each field for the lesions located on the left and right side of the back was 1500 cGy. This therapy resulted in significant reduction of visible tumor. The patient was regularly followed up on outpatient basis for 12 months of radiotherapy, being free from local recurrence and systemic spread of the disease.

1 January 2010
Verified
Journal Article
Closed access
DBDaška Stulhofer Buzina
Daška Stulhofer Buzina
JLJasna Lipozenčić
Jasna Lipozenčić
ZMZrinka Bukvić Mokos
Zrinka Bukvić Mokos
RCRomana Ceović
Romana Ceović
KKKrešimir Kostović
Krešimir Kostović

1 January 2012
Verified
Journal Article
Closed access
RČRomana Čeović
Romana Čeović
NSNikolina Smolković
Nikolina Smolković
APAida Pašić
Aida Pašić
KKKrešimir Kostović
Krešimir Kostović
DHDamir Hrsan
Damir Hrsan

1 January 2015
Verified
Journal Article
Closed access
TRTamara Čuk Radović
Tamara Čuk Radović
KKKrešimir Kostović
Krešimir Kostović
JRJaka Radoš
Jaka Radoš
ZPZrinjka Paštar
Zrinjka Paštar
GPGordana Pavliša
Gordana Pavliša
MSMirna Situm
Mirna Situm